300702.SHE Zhejiang Tianyu Pharmaceutical Co Ltd
- Market cap
- CNY 7.10B
- P/E
- 97.1x
- P/B
- 1.91x
- ROE
- 5.6%
- Dividend yield
- 0.82%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300702.SHE undervalued?
Graham number300702.SHE trades 187.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Tianyu Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Tianyu Pharmaceutical Co Ltd yet.
Zhejiang Tianyu Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine chemicals and CDMO services. The company was founded in 1993 and is headquarter…
Full company profileZhejiang Tianyu Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Tianyu Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.08B | 1.19B | 1.47B | 2.11B | 2.59B | 2.55B | 2.67B | 2.53B | 2.63B | 3.06B | 4.02B |
| Gross Profit | 395M | 434M | 572M | 1.13B | 1.29B | 907M | 591M | 850M | 870M | 1.14B | 1.26B |
| Operating Income | 138M | 120M | 196M | 688M | 776M | 240M | -102M | 70.7M | 84.9M | 304M | 389M |
| EBITDA | 212M | 233M | 298M | 778M | 856M | 371M | 165M | 440M | 432M | 560M | 258M |
| Net Income | 122M | 100M | 164M | 586M | 667M | 205M | -119M | 27.4M | 55.9M | 140M | 201M |
| EPS | 0.51 | 0.38 | 0.51 | 1.79 | 2.05 | 0.59 | -0.34 | 0.08 | 0.16 | 0.40 | 0.58 |
| Balance Sheet | |||||||||||
| Total Assets | 1.52B | 2.11B | 2.63B | 2.84B | 4.89B | 5.80B | 6.42B | 6.34B | 6.58B | 6.59B | 6.80B |
| Total Liabilities | 908M | 819M | 1.18B | 803M | 1.34B | 2.09B | 2.92B | 2.85B | 3.08B | 2.95B | 3.15B |
| Shareholders' Equity | 607M | 1.29B | 1.45B | 2.04B | 3.55B | 3.71B | 3.50B | 3.49B | 3.50B | 3.64B | 3.60B |
| Cash & Short-term Investments | 181M | 222M | 346M | 142M | 1.33B | 550M | 477M | 426M | 593M | 512M | 497M |
| Total Debt | 487M | 338M | 484M | 53.8M | 264M | 637M | 1.29B | 1.74B | 1.74B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 165M | 88.5M | 78.6M | 428M | 622M | -262M | -48.7M | -43.9M | 345M | 474M | - |
| Capital Expenditure | 107M | 113M | 180M | 354M | 506M | 736M | 527M | 317M | 169M | 358M | 235M |
| Free Cash Flow | 57.3M | -24.0M | -101M | 73.7M | 116M | -999M | -576M | -361M | 176M | 116M | 541M |
| Ratios | |||||||||||
| ROE | 20.1% | 7.8% | 11.3% | 28.8% | 18.8% | 5.5% | -3.4% | 0.8% | 1.6% | 3.8% | 5.6% |
| ROA | 8.1% | 4.8% | 6.2% | 20.6% | 13.6% | 3.5% | -1.9% | 0.4% | 0.9% | 2.1% | 3.0% |
| Net Profit Margin | 11.3% | 8.4% | 11.2% | 27.8% | 25.8% | 8.0% | -4.5% | 1.1% | 2.1% | 4.6% | 5.0% |
| Debt to Equity | 0.80x | 0.26x | 0.33x | 0.03x | 0.07x | 0.17x | 0.37x | 0.50x | 0.50x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Tianyu Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.82%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 41.5%
- Ex-dividend date
- Jun 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 58.0M | 0.17 | 41.5% |
| 2024 | CNY 70.2M | 0.20 | 125.5% |
| 2023 | CNY 51.1M | 0.15 | 186.8% |
| 2022 | CNY 34.8M | 0.10 | - |
| 2021 | CNY 96.7M | 0.28 | 47.2% |
| 2020 | CNY 91.1M | 0.28 | 13.7% |
| 2019 | CNY 27.3M | 0.08 | 4.7% |
| 2018 | CNY 36.6M | 0.11 | 22.4% |
| 2017 | CNY 53.6M | 0.21 | 53.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.8:1 on Jun 18, 2021.
Who owns Zhejiang Tianyu Pharmaceutical Co Ltd
- Insiders 53.95%
- Institutions 14.36%
- Public & others 31.68%
- Shares outstanding 348M
- Free float 165M
Zhejiang Tianyu Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Tianyu Pharmaceutical Co Ltd
- Ticker
- 300702.SHE
- ISIN
- CNE1000034X1
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,686
- Fiscal year end
- December
- Address
- Huangyan Jiangkou Chemical Dev Zn, Taizhou, China, 318020
- Phone
- 86 576 8918 9669
- Website
- tianyupharm.com
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine chemicals and CDMO services. The company was founded in 1993 and is headquartered in Taizhou, China.
Zhejiang Tianyu Pharmaceutical Co Ltd management
6- Mr. Yong Jun TuChairman & GM · born 1963
- Mr. Guo Rong ZhuDeputy GM & Non-Independent Director · born 1975
- Mr. Chuanliang DengDeputy GM & Non-Independent Director · born 1974
- Mr. Fujun WangDeputy General Manager · born 1973
- Ms. Yan WangBoard Secretary & Deputy GM · born 1980
- Ms. Chong WangCFO & Accounting Supervisor · born 1982